PUMA BIOTECHNOLOGY, INC. — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/b38f9edb-828d-4ec4-86d3-058f6b0d23fc/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $228.4M | 2025-01-01 – 2025-12-31 | evidence 0001437749-26-005891 |
| FY 2024 | $230.5M | 2024-01-01 – 2024-12-31 | evidence 0001437749-25-005496 |
| FY 2023 | $235.6M | 2023-01-01 – 2023-12-31 | evidence 0001437749-24-006121 |
| FY 2022 | $228.0M | 2022-01-01 – 2022-12-31 | evidence 0001437749-23-005233 |
| FY 2021 | $253.2M | 2021-01-01 – 2021-12-31 | evidence 0001437749-22-005164 |
| FY 2020 | $225.1M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-009840 |
| FY 2019 | $272.3M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-007591 |
| FY 2018 | $251.0M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-005830 |
| FY 2017 | $27.7M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-005830 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
PUMA BIOTECHNOLOGY, INC. — all facts · Net Income · Operating Income